Walgreens Boots Alliance, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends

SG&A Expense Trends: Walgreens vs. Celldex

__timestampCelldex Therapeutics, Inc.Walgreens Boots Alliance, Inc.
Wednesday, January 1, 20142062200017992000000
Thursday, January 1, 20153383700022400000000
Friday, January 1, 20163597900023910000000
Sunday, January 1, 20172500300023813000000
Monday, January 1, 20181926900024694000000
Tuesday, January 1, 20191542600023557000000
Wednesday, January 1, 20201445600025436000000
Friday, January 1, 20212048800024586000000
Saturday, January 1, 20222719500027295000000
Sunday, January 1, 20233091400034205000000
Monday, January 1, 202428113000000
Loading chart...

Data in motion

SG&A Expense Trends: Walgreens Boots Alliance vs. Celldex Therapeutics

In the ever-evolving landscape of the pharmaceutical and retail sectors, understanding the financial dynamics of key players is crucial. Over the past decade, Walgreens Boots Alliance, Inc. and Celldex Therapeutics, Inc. have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. Walgreens, a retail giant, consistently reported SG&A expenses exceeding $17 billion annually, peaking at approximately $28 billion in 2024. This reflects a steady growth trajectory, with a notable 44% increase from 2014 to 2024. In contrast, Celldex, a smaller biotech firm, experienced more volatility, with expenses ranging from $14 million to $36 million, highlighting a 75% increase from 2014 to 2023. These trends underscore the differing operational scales and strategic priorities of these companies, offering valuable insights into their financial health and market strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025